Browsing Radiotherapy and Imaging by author "Dearnaley, David"
Now showing items 1-20 of 62
-
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
Bancroft, EK; Page, EC; Brook, MN; Thomas, S; Taylor, N; et al. (ELSEVIER SCIENCE INC, 2021-10-19)BACKGROUND: Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and ... -
A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases.
Denis-Bacelar, AM; Chittenden, SJ; Murray, I; Divoli, A; Ralph McCready, V; et al. (IOP PUBLISHING LTD, 2017-04-07)Skeletal tumour burden is a biomarker of prognosis and survival in cancer patients. This study proposes a novel method based on the linear quadratic model to predict the reduction in metastatic tumour burden as a function ... -
A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.
Murray, J; Griffin, C; Gulliford, S; Syndikus, I; Staffurth, J; et al. (ELSEVIER IRELAND LTD, 2020-01-01)BACKGROUND AND PURPOSE: Image-guided radiotherapy (IGRT) improves treatment set-up accuracy and provides the opportunity to reduce target volume margins. We introduced IGRT methods using standard (IGRT-S) or reduced (IGRT-R) ... -
A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact.
Macinnis, RJ; Antoniou, AC; Eeles, RA; Severi, G; Al Olama, AA; et al. (WILEY, 2011-07-18)Genome wide association studies have identified several single nucleotide polymorphisms (SNPs) that are independently associated with small increments in risk of prostate cancer, opening up the possibility for using such ... -
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
James, ND; de Bono, JS; Spears, MR; Clarke, NW; Mason, MD; et al. (MASSACHUSETTS MEDICAL SOC, 2017-07-27)BACKGROUND: Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a ... -
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
Hoyle, AP; Ali, A; James, ND; Cook, A; Parker, CC; et al. (ELSEVIER, 2019-12-01)BACKGROUND: Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen in the ... -
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Sydes, MR; Spears, MR; Mason, MD; Clarke, NW; Dearnaley, DP; et al. (OXFORD UNIV PRESS, 2018-05-01)BACKGROUND: Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation ... -
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
Mason, MD; Clarke, NW; James, ND; Dearnaley, DP; Spears, MR; et al. (AMER SOC CLINICAL ONCOLOGY, 2017-05-10)Purpose Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage, platform design. It recruits men with high-risk, locally ... -
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
Woods, BS; Sideris, E; Sydes, MR; Gannon, MR; Parmar, MKB; et al. (ELSEVIER, 2018-12-01)BACKGROUND: Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate cancer (PC) prolongs survival for those with ... -
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Clarke, NW; Ali, A; Ingleby, FC; Hoyle, A; Amos, CL; et al. (OXFORD UNIV PRESS, 2019-12-01)BACKGROUND: STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report ... -
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James, ND; Sydes, MR; Clarke, NW; Mason, MD; Dearnaley, DP; et al. (ELSEVIER SCIENCE INC, 2016-03-19)BACKGROUND: Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with ... -
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Ali, A; Hoyle, A; Haran, ÁM; Brawley, CD; Cook, A; et al. (AMER MEDICAL ASSOC, 2021-04-01)IMPORTANCE: Prostate radiotherapy (RT) improves survival in men with low-burden metastatic prostate cancer. However, owing to the dichotomized nature of metastatic burden criteria, it is not clear how this benefit varies ... -
Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy.
Denis-Bacelar, AM; Chittenden, SJ; McCready, VR; Divoli, A; Dearnaley, DP; et al. (BRITISH INST RADIOLOGY, 2018-01-01)OBJECTIVE: The aim of this study was to calculate the range of absorbed doses that could potentially be delivered by a variety of radiopharmaceuticals and typical fixed administered activities used for bone pain palliation ... -
Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment.
Hafeez, S; McDonald, F; Lalondrelle, S; McNair, H; Warren-Oseni, K; et al. (ELSEVIER SCIENCE INC, 2017-05-01)PURPOSE AND OBJECTIVES: We report on the clinical outcomes of a phase 2 study assessing image guided hypofractionated weekly radiation therapy in bladder cancer patients unsuitable for radical treatment. METHODS AND ... -
Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.
Ahmed, M; Dorling, L; Kerns, S; Fachal, L; Elliott, R; et al. (NATURE PUBLISHING GROUP, 2016-05-10)BACKGROUND: Numerous germline single-nucleotide polymorphisms increase susceptibility to prostate cancer, some lying near genes involved in cellular radiation response. This study investigated whether prostate cancer ... -
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
Clarke, CS; Hunter, RM; Gabrio, A; Brawley, CD; Ingleby, FC; et al. (PUBLIC LIBRARY SCIENCE, 2022-01-01)Adding abiraterone acetate (AA) plus prednisolone (P) to standard of care (SOC) improves survival in newly diagnosed advanced prostate cancer (PC) patients starting hormone therapy. Our objective was to determine the value ... -
Derivation of Dose/Volume Constraints for the Anorectum from Clinician- and Patient-Reported Outcomes in the CHHiP Trial of Radiation Therapy Fractionation.
Wilkins, A; Naismith, O; Brand, D; Fernandez, K; Hall, E; et al. (ELSEVIER SCIENCE INC, 2020-04-01)PURPOSE: The CHHiP trial randomized 3216 men with localized prostate cancer (1:1:1) to 3 radiation therapy fractionation schedules: 74 Gy in 37 fractions over 7.4 weeks; 60 Gy in 20 fractions over 4 weeks; and 57 Gy in 19 ... -
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
James, ND; Ingleby, FC; Clarke, NW; Amos, CL; Attard, G; et al. (OXFORD UNIV PRESS, 2022-07-01)BACKGROUND: STAMPEDE previously reported adding upfront docetaxel improved overall survival for prostate cancer patients starting long-term androgen deprivation therapy. We report long-term results for non-metastatic ... -
Dosimetry and Gastrointestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node Radiotherapy in Advanced Localised Prostate Cancer.
Ferreira, MR; Thomas, K; Truelove, L; Khan, A; Parker, C; et al. (ELSEVIER SCIENCE LONDON, 2019-06-01)AIMS: Pelvic lymph node (PLN) radiotherapy for high-risk prostate cancer is limited by late gastrointestinal toxicity. Application of rectal and bowel constraints may reduce risks of side-effects. We evaluated associations ... -
Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital.
Bianchini, D; Lorente, D; Rescigno, P; Zafeiriou, Z; Psychopaida, E; et al. (CIG MEDIA GROUP, LP, 2017-10-01)BACKGROUND: The optimal management of the primary tumor in metastatic at diagnosis (M1) prostate cancer (PCa) patients is not yet established. We retrospectively evaluated the effect of locoregional treatment (LRT) on ...